Breast Cancer Treatment in China: Subtype, Hospitals and Cost Drivers

Breast cancer care in China for international patients: HR-positive, HER2-positive and triple-negative pathways, when breast-conserving surgery is realistic, named centres, and why drugs usually move the bill more than the operation.

7500+

patients treated

10

years of experience

50+

partner clinics

Breast: subtype picks the protocol

HR-positive
Endocrine backbone, CDK4/6 in indicated lines. Months of drug, not a two-week tour.
HER2-positive
Anti-HER2 agents usually dwarf the operating-room line. Names must be on the quote.
Triple-negative
Chemo +/- IO when indicated. Conserving surgery still needs a radiation story.
QuestionUsual comparisonCost note
Conserving surgery + radiationFudan, CAMS/NCC, PKU Cancer, SYSUCCOR + stay + RT calendar — not one SKU
HER2 / CDK4/6 / TNBC-IO drugsSame public breast unitsOften the largest line — list names
Selected left-sided / re-irradiation protonSPHIC / Ruijin if geometry fits~USD 20-35k course band if accepted
Breast CAR-T adTrial claim until namedDo not use blood-cancer CAR-T prices

Cancer hub · Cost drivers · Hospitals

What the medical trip includes

  • 📋

    Subtype before a hospital name

    ER/PR, HER2, grade, nodes. TNBC, HER2+ and HR+ do not share a brochure.

  • 🏥

    Breast unit, not a ranking

    Fudan, CAMS/NCC, PKU Cancer, SYSUCC. Conserving surgery needs a radiation plan in the same story.

  • ✈️

    Drugs outlast the flight

    HER2 agents, CDK4/6, IO in selected TNBC. The medical PDF that hides drug names is not a quote.

Why patients choose us

  • ✅

    Conserving vs mastectomy labelled

    We do not sell reconstruction as proof of a better oncology plan.

  • 💬

    Drug drivers on the table

    The expensive line is often months of targeted therapy, not the operating room.

  • 🌍

    Same hospital map as the hub

    No second mythology. Fuda is compared, not assumed.

How it works

  • 01

    Send receptors and staging

    Plus prior surgery or systemic therapy. Missing HER2 status blocks a real shortlist.

  • 02

    Pick the sequence

    Neoadjuvant vs upfront surgery, radiation need, targeted/endocrine plan.

  • 03

    Travel after the unit accepts

    Invitation, visa, interpreter. Reconstruction, if wanted, is a separate consent.

Treatment package costs

  • Breast file review

    No charge to start

    Subtype split • Surgery/radiation note • Centre shortlist • Drug-driver warning

  • Coordinated trip

    Quoted after records

    Hospital matching • Itemised drivers • Visa • Interpreter

Who this is for

  • Early-stage patients seeking conserving surgery

    Need a unit that will say yes or no after imaging, with radiation in the same plan.

  • HER2+ or TNBC needing systemic sequencing

    Need drug names and line of therapy, not a two-week package.

  • Metastatic patients after several lines

    Need honest control goals and a centre that will read the full chemo history.

Frequently asked questions

  • Is breast-conserving surgery available in China?

    Yes, at high-volume centres when tumour size, location and staging allow, usually with a radiation plan. It is not guaranteed from a photo. The surgeon decides after imaging.

  • Do HR+, HER2+ and TNBC use the same protocol?

    No. Receptor status changes drugs, sequencing and sometimes the case for neoadjuvant therapy. Missing ER/PR/HER2 is not a complete file.

  • Which hospitals for breast cancer?

    Common comparison set: Fudan, CAMS/NCC, PKU Cancer, SYSUCC. Add a radiation or proton question only when the geometry needs it. Fuda is not automatic.

  • Is CAR-T used for breast cancer?

    Not as standard care. Treat any ‘breast CAR-T in China’ offer as a trial claim until a named protocol and centre confirm it.

  • How is cost estimated?

    Surgery and a few inpatient days are one basket. Targeted and endocrine drugs over months are another, often larger. We will not publish a fake all-in breast price. See the cost page for how to read a letter.

  • What records are required?

    Pathology with ER/PR/HER2, operative and chemo history if any, staging imaging, current meds. BRCA/HRD helps when it exists — it is not mandatory to start a review.

  • Is stage 4 breast cancer treated?

    Yes, mainly systemic therapy with selected local control. Goals are often disease control. We do not promise a cure.

More about treatment in China

Breast cancer treatment in China follows subtype and stage, not a shopping list of hospitals. HR-positive, HER2-positive and triple-negative disease are different protocols. A file without ER/PR, HER2 (IHC/FISH) and a clear surgical history produces a brochure. Breast-conserving surgery plus radiation is available at high-volume centres when the anatomy and staging allow; mastectomy and reconstruction questions are separate decisions, not upgrades. Centres that come up: Fudan University Shanghai Cancer Center, CAMS / National Cancer Center, Peking University Cancer Hospital, Sun Yat-sen University Cancer Center. Proton is uncommon and only for selected left-sided or re-irradiation geometries. CAR-T is not standard breast-cancer care. Fuda is not the default breast-conserving public department — compare the actual method. Cost is usually a drug story more than a knife story: HER2-targeted agents, CDK4/6 inhibitors, immunotherapy in selected TNBC, endocrine duration, and whether radiation is in the same city as surgery. There is no honest single ‘breast cancer in China’ price. Stage 4 goals are typically control. Send pathology with receptors, operative notes if already operated, staging imaging and current meds.
Home
Menu
Search
Инфо